FDA Warns Compounder It’s Not Exempt From Oversight

Drug Industry Daily
The FDA sent a warning letter to compounder Gipsco Investment cautioning that it’s not exempt from the agency’s oversight and was producing adulterated and misbranded products. The action stems from a June 2017 inspection of the Cleveland, Ohio, facility.

To View This Article:


Subscribe To Drug Industry Daily